Cancer immunotherapy company EpicentRx raises $35m in Series D round
EpicentRx, a cancer immunotherapy company based in California, has secured $35 million of capital through a Series D financing round to support the development of small molecule immunotherapy and its oncolytic viral platform. The oncology company used the services of Biotech Alliances International, a Silicon Valley based life-science focused investment bank to get the funding. […]